Condition: Advanced or Metastatic Non-small Cell Lung Cancer · Sponsor: AstraZeneca
The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Phoenix, Arizona, United States | Recruiting |
| Research Site | Santa Rosa, California, United States | Recruiting |
| Research Site | Jacksonville, Florida, United States | Recruiting |
| Research Site | Baltimore, Maryland, United States | Recruiting |
| Research Site | Detroit, Michigan, United States | Not Yet Recruiting |
| Research Site | Rochester, Minnesota, United States | Recruiting |
| Research Site | Cleveland, Ohio, United States | Recruiting |
| Research Site | Providence, Rhode Island, United States | Recruiting |
| Research Site | Providence, Rhode Island, United States | Withdrawn |
| Research Site | Tyler, Texas, United States | Recruiting |
| Research Site | Anderlecht, Belgium | Not Yet Recruiting |
| Research Site | Hasselt, Belgium | Not Yet Recruiting |
+ 91 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06996782